We target cures for diseases
of people, and
for which there
are significant unmet needs.
Immtech has a cost-effective drug development paradigm in the
Targeting Diseases in Need of New Treatments
We aim to develop cures for infectious diseases that affect the global community
and for which there are significant unmet needs. Although the infectious disease
market represents an estimated US$46 billion in annual sales, relatively few new
drugs have been developed to treat infectious diseases during the last twenty years.
Accelerating the Pace, and Reducing the Cost, of Commercialization
Immtech focuses on moving compounds from discovery to commercialization at a fraction
of the cost of similar development efforts at large pharmaceutical companies. We
accomplish this by using our Scientific Consortium, a group of scientists who perform
early-stage discovery research. By tapping into the expertise of these university-based
researchers, Immtech aims to identify promising research platforms and develop drug
Innovative Funding Strategies
In addition to fundraising in the equity markets, we have funded part of our discovery
costs with non-dilutive sources that include grants from the National Institutes of
Health (NIH) and other foundations. Through members of the Immtech Scientific Consortium,
led by the University of North Carolina at Chapel Hill, we have also received funding from
the Bill and Melinda Gates Foundation.
© 2008 Immtech. All Rights Reserved